查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179874

2023-2030 年全球肌肉骨骼疾病治療市場

Global Musculoskeletal Diseases Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2023-2030)，肌肉骨骼疾病治療的全球市場規模預計將以 4.8% 的複合年增長率增長。

肌肉、骨骼、關節和附近結締組織的功能障礙，導致暫時或永久的功能限制和受累，構成了 150 多種不同的疾病和病症，稱為肌肉骨骼疾病。我在這裡。 主要的肌肉骨骼疾病比其他常見疾病的治療費用更高，因為它們通常會導致長期疼痛和殘疾。

市場動態

推動全球肌肉骨骼疾病治療市場的主要因素是肌肉骨骼疾病數量的增加、肌肉骨骼疾病治療技術的發展以及公眾對肌肉骨骼疾病驅動市場的比例的認識提高。有一個東西.

市場的主要驅動力是肌肉骨骼疾病的增加，預計這將推動市場增長。

世界衛生組織估計，到 2022 年，全球將有 17.1 億人受到肌肉骨骼疾病的影響。 在 160 個不同的國家，背痛是唯一的殘疾原因，而肌肉骨骼疾病是全世界殘疾的主要原因。 肌肉骨骼疾病嚴重限制了運動和靈活性，導致提前退休、幸福感下降以及參與社會的能力下降。 由於人口增長和老齡化，患有肌肉骨骼疾病和相關功能受限的人數不斷增加。

根據關節炎 2021，英國有超過 2000 萬人（約佔人口的三分之一）患有肌肉骨骼系統 (MSK) 疾病，例如關節炎和背痛。 患有關節炎等 MSK 疾病的患者通常會感到疲勞、僵硬、行動不便和靈活性下降，以及疼痛，這是這些疾病的主要症狀之一。 因此，新興市場參與者在採用肌肉骨骼疾病療法方面具有顯著的市場領先優勢。

高昂的處理成本可能會減緩市場擴張。

市場預計將受到高研發成本和復雜行政程序的阻礙。 此外，醫院主要擔心的是治療肌肉骨骼疾病的潛在副作用將使市場停滯。

COVID-19 影響分析

在全球範圍內，COVID-19 大流行對醫療保健系統產生了不利影響。 許多行業參與者的活動和業績受到大流行的影響，活動逐漸減少。 此外，2020年上半年，肌肉骨骼疾病治療市場受到COVID-19大流行的嚴重影響。 在大流行的早期階段，封鎖的迅速實施擾亂了分銷網絡。 此外，由於全世界都在集中精力抗擊病毒，肌肉骨骼疾病的治療也被中斷或延遲。 COVID-19 的典型症狀類似於風濕病和肌肉骨骼疾病的症狀，因此很難對這些症狀進行適當和最佳的治療。

此外，用於治療 COVID-19 感染的各種抗病毒藥物的副作用使問題進一步複雜化。 但在月子事件後，市場逐漸復蘇，治療肌肉骨骼疾病的藥物需求增加，加強了供應鏈。 此外，製藥公司正在開發先進的藥物來治療疾病，以便患者可以選擇更有效的治療方法。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 市場的主要驅動因素是肌肉骨骼疾病的增加。
      • 治療肌肉骨骼疾病的技術發展
    • 約束因素
      • 飆升的治療費用可能會阻礙市場擴張
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疾病類型分類

  • 關節炎
  • 骨關節炎
  • 骨質疏鬆症
  • 脊椎炎
  • 創傷性骨折
  • 肌肉減少症
  • 纖維肌痛
  • 其他

第 8 章按成像方式

  • 磁共振成像 (MRI)
  • 計算機斷層掃描 (CT)
  • 超聲診斷設備
  • 其他

第9章藥物

  • 對乙□氨基酚
  • 非甾體抗炎藥 (NSAID)
  • 抗神經性止痛藥
  • 其他

第 10 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • 輝瑞
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Koninklijke Philips
  • Siemens
  • Canon Medical Systems
  • Hitachi
  • Shimadzu
  • Fujifilm
  • Toshiba
  • Accuray
  • MR Solutions
  • Globus Medical Inc

第14章 DataM

簡介目錄
Product Code: DMPH6109

Market Overview

The global musculoskeletal diseases treatment market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Muscle, bone, joint, and nearby connective tissue dysfunction resulting in temporary or permanent restrictions in functioning and involvement make up over 150 different diseases and conditions known as musculoskeletal impairments. Major musculoskeletal diseases are more expensive to treat than other common medical conditions because they frequently cause long-term pain and disability.

Market Dynamics

The major factors driving the global musculoskeletal diseases treatment market are due to the market is primarily being driven by a rise in the number of musculoskeletal diseases, technological developments in the treatment of musculoskeletal diseases and increasing public awareness of the rate of musculoskeletal diseases.

The market is primarily being driven by a rise in the number of musculoskeletal diseases is expected to drive the market's growth.

World Health Organization estimates that 1.71 billion people worldwide will suffer from musculoskeletal diseases in 2022. Low back pain is the sole cause of disability in 160 different nations, and musculoskeletal diseases are the main cause of disability globally. Musculoskeletal disorders severely restrict movement and dexterity, which results in early retirement from the workforce, decreased levels of well-being, and a decreased capacity to engage in society. The number of people with musculoskeletal diseases and related functional restrictions is constantly rising due to population expansion and aging.

Over 20 million people in the UK (approximately a third of the population), according to versus arthiritis 2021, suffer from musculoskeletal (MSK) conditions like arthritis and low back pain. Patients with MSK diseases like arthritis usually suffer pain, which is one of the main symptoms of these conditions, in addition to fatigue, stiffness, and a loss of movement and dexterity. As a result, key players in developing nations have significant advantages in leading the market by adopting musculoskeletal illness treatment.

The high cost of treatment could slow market expansion.

The market is anticipated to be hampered by expensive R&D expenses and a complicated government process. Additionally, the hospitals' main fear is that the potential for side effects from the treatment of musculoskeletal diseases would halt the market.

COVID-19 Impact Analysis

Globally, the COVID-19 pandemic had a detrimental effect on healthcare systems. Many industry players' activities and financial results have been impacted by the Pandemic and the gradually declining of activities. Additionally, in the first half of 2020, the market for the treatment of musculoskeletal diseases was significantly impacted by the COVID-19 epidemic. During the Pandemic's early stages, the distribution network was hampered by the rapid implementation of lockdown. Furthermore, while the globe concentrated on the virus-fighting effort, treatments for musculoskeletal diseases were suspended or delayed. The typical COVID-19 manifestations, which can mimic the symptoms of rheumatic and musculoskeletal diseases, make it difficult to treat these conditions appropriately and optimally.

Additionally, the side effects of the various antiviral medications used to treat COVID-19 infection further complicate matters. However, the market gradually recovered following the lockdown, which increased the demand for medications for musculoskeletal disorders and strengthened the supply chain. In addition, pharmaceutical companies are developing advanced disease medications to encourage patients to choose more effective therapies.

Segment Analysis

The arthritis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Arthritis is the most prevalent disease type in the musculoskeletal disease treatment market. Inflammation of one or more joints, such as the knees, knuckles, wrists, or ankles, is known as arthritis or joint disease. Joint pain, edema, and stiffness can develop as arthritis progresses from its first stage of joint inflammation. The CDC estimates that approximately 58.5 million Americans, or one out of four US adults (23.7%), have arthritis that a doctor has officially diagnosed.

Women are more likely to have arthritis (23.5%) than men (18.1%), it is more prevalent in adults with fair or poor health (40.5%) than in adults with excellent or very good health (15.4%), and it is less prevalent in adults who meet physical activity guidelines (18.1%) than in adults who are insufficiently active or inactive (23.1% and 23.6%, respectively). Age is a factor in the prevalence of arthritis. Drugs frequently treat arthritis because they can lessen inflammation and persistent pain. Anti-inflammatory drugs sold over the counter and painkillers may reduce arthritic discomfort. Corticosteroids can lower inflammation and suppress the immune system.

Geographical Analysis

North America holds the largest market share in the global musculoskeletal diseases treatment market.

North America dominates the global musculoskeletal diseases treatment market has a major influence on adopting various medical procedures. The treatment of musculoskeletal diseases market is growing in North America due to the rising prevalence of inflammatory bowel diseases and the availability of more hospitals and improved diagnostics facilities. The United States Bone and Joint Initiative (USBJI) predicts that by 2040, 1 in 5 U.S Americans will be 65 or older, roughly equaling the proportion of people in that age group.

Nearly two-thirds of people with arthritis are under 65, even though one in two adults aged 65 and older already has some arthritis. 67 million persons are expected to have arthritis by the year 2030. Both inflammatory types of osteoarthritis and inflammatory forms of arthritis are more common in women. Additionally, over the next few years, it is anticipated that the critical healthcare benefits provided by employer-sponsored health insurance plans and the growing investments by vendors in cutting-edge and affordable medications will boost this regional market.

Competitive Landscape

The musculoskeletal diseases treatment market is moderately competitive with local and global companies' presence Pfizer, Koninklijke Philips, Siemens, Canon Medical Systems, Hitachi, Shimadzu, Fujifilm, Toshiba, Accuray, MR Solutions, Globus Medical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth.

Globus Medical Inc.

Overview: A manufacturer of medical devices, Globus Medical Inc. (Globus) creates and markets healthcare products for persons with musculoskeletal diseases. The business provides surgical instruments, biologics, accessories, and implanted devices for various spinal, orthopedic, and neurosurgery treatments. Ankle fracture system, clavicle fracture system, distal radius fracture system, proximal tibia fracture system, and small fragment fracture system are some of its main offerings. Additionally, it provides clever computer-assisted systems intended to enhance surgeons' capabilities and simplify surgical procedures.

Product Portfolio:

ANTHEM Ankle Fracture System: Three types of distal fibula plates are available with contours to match patient anatomy and minimize the need for intraoperative bending. Low profile plates are designed for minimal screw prominence to help reduce soft tissue irritation. Clamps designed specifically for ankle anatomy facilitate fracture reduction. Radiolucent Weitlaners and retractors aid in fracture site visibility.

The global musculoskeletal diseases treatment market report would provide access to approx.: 45 + market data table, 40 + figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The market is primarily being driven by a rise in the number of musculoskeletal diseases
      • 4.1.1.2. Technological developments in the treatment of musculoskeletal diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of treatment could slow market expansion
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Arthritis
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Osteoarthritis
  • 7.4. Osteoporosis
  • 7.5. Spondylitis
  • 7.6. Traumatic fractures
  • 7.7. Sarcopenia
  • 7.8. fibromyalgia
  • 7.9. Others

8. By Imaging Modality

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 8.1.2. Market Attractiveness Index, By Imaging Modality
  • 8.2. Magnetic Resonance Imaging (MRI)
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Computed Tomography (CT)
  • 8.4. Ultrasound
  • 8.5. Others

9. By Medication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 9.1.2. Market Attractiveness Index, By Medication
  • 9.2. Acetaminophen
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • 9.4. Anti-neuropathic pain medications
  • 9.5. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacy
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Imaging Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Pfizer
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Koninklijke Philips
  • 13.3. Siemens
  • 13.4. Canon Medical Systems
  • 13.5. Hitachi
  • 13.6. Shimadzu
  • 13.7. Fujifilm
  • 13.8. Toshiba
  • 13.9. Accuray
  • 13.10. MR Solutions
  • 13.11. Globus Medical Inc

LIST NOT EXHAUSTIVE

14. Global Musculoskeletal diseases treatment Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us